Skip to content

Intrathecal Morphine vs Transversalis Fascia Plane Block After Cesarean Delivery

Comparison of Intrathecal Morphine and Ultrasound-Guided Bilateral Transversalis Fascia Plane Block for Post-Cesarean Analgesia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07374133
Enrollment
60
Registered
2026-01-28
Start date
2026-02-01
Completion date
2026-03-15
Last updated
2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Delivery, Obstetric Anesthesia, Postoperative Analgesia

Keywords

Cesarean Sections, Postoperative Pain, Analgesia, Ultrasonography, Interventional, Spinal Anesthesia

Brief summary

This prospective single-center study compares intrathecal morphine and ultrasound-guided bilateral transversalis fascia plane block for postoperative analgesia in patients undergoing elective cesarean delivery under spinal anesthesia. The primary outcome is the number of parturients requiring rescue analgesia within the first 24 hours postoperatively. The secondary outcomes include postoperative pain scores, rescue analgesia requirement, nausea/vomiting, pruritus, and obstetric quality of recovery (ObsQoR-11).

Detailed description

This prospective single-center study investigates postoperative acute pain management in parturients aged 18-45 years undergoing elective cesarean delivery under spinal anesthesia.Participants will be followed as a single prospective cohort, and postoperative outcomes will be compared between exposure groups defined by the routine clinical analgesic approach (intrathecal morphine or ultrasound-guided bilateral transversalis fascia plane block).A total of 60 patients are planned to be enrolled. Eligible participants are term parturients with a gestational age greater than 37 weeks, classified as American Society of Anesthesiologists (ASA) physical status II, and scheduled for elective cesarean delivery under spinal anesthesia. Patients will be excluded if they refuse participation, undergo cesarean delivery under general anesthesia, have ASA physical status greater than III, multiple pregnancy, conversion to general anesthesia after spinal anesthesia, contraindications to central or peripheral regional anesthesia techniques, body mass index greater than 35 kg/m², known allergy or hypersensitivity to local anesthetics or opioids, or significant organ dysfunction such as severe hepatic or renal disease. In routine clinical practice, the postoperative analgesic approach is determined through shared decision-making based on patient preference and the responsible anesthesiologist's clinical assessment. Accordingly, two postoperative analgesic strategies will be compared: addition of intrathecal morphine to spinal anesthesia and ultrasound-guided bilateral transversalis fascia plane block. Following standard ASA monitoring, spinal anesthesia is performed in the sitting position at the L4-5 interspace using a 26-gauge spinal needle. After confirmation of free cerebrospinal fluid flow, 12.5 mg of 0.5% hyperbaric bupivacaine combined with 20 micrograms of fentanyl is administered intrathecally. In the intrathecal morphine group, 100 micrograms of morphine is added to the intrathecal anesthetic solution. Sensory block level is assessed using the pinprick test, and surgery is initiated when a T6 sensory level is achieved. In the transversalis fascia plane block group, the block is performed in the postoperative period with the patient in the supine position. An ultrasound probe is placed transversely just cranial to the iliac crest, and the abdominal wall layers, transversalis fascia, retroperitoneal fat, and peritoneum are identified. Using an in-plane needle approach, after hydrodissection with 3 mL of normal saline, 20 mL of 0.25% bupivacaine is injected into the plane deep to the transversalis fascia. The procedure is repeated on the contralateral side. For postoperative nausea and vomiting prophylaxis, 4 mg of intravenous ondansetron is administered near skin closure, and uterotonic agents are given according to institutional protocols. Postoperative analgesia consists of 1 g intravenous paracetamol every 8 hours and intramuscular diclofenac every 12 hours. When the Numeric Rating Scale (NRS) score exceeds 4, rescue analgesia is provided with 100 mg intravenous tramadol administered as a 30-minute infusion, with a maximum daily dose of 300 mg. The primary outcome of the study is the number of participants requiring rescue analgesia within the first 24 hours postoperatively. Secondary outcomes include postoperative pain intensity assessed using the NRS at rest and during activity at 0, 3, 6, 12, and 24 hours; incidence and severity of postoperative nausea and vomiting assessed using a 0-4 verbal rating scale; incidence and severity of pruritus assessed using a 0-3 scale at the same time points; and patient satisfaction and quality of recovery assessed using the Obstetric Quality of Recovery-11(ObsQoR-11) questionnaire at 24 and 48 hours after surgery. All data will be collected by an anesthesia resident not involved in the procedures, anonymized, and handled in accordance with the Declaration of Helsinki. The study will be reported in compliance with the STROBE reporting guidelines, and participant confidentiality will be strictly maintained.

Interventions

None listed

Sponsors

Ondokuz Mayıs University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Female parturients aged 18 to 45 years * Gestational age greater than 37 weeks * American Society of Anesthesiologists (ASA) physical status II * Scheduled for elective cesarean delivery under spinal anesthesia * Willingness to participate in the study

Exclusion criteria

* Refusal to participate in the study * Cesarean delivery performed under general anesthesia * Conversion to general anesthesia after spinal anesthesia * ASA physical status greater than III * Multiple pregnancy * Contraindications to central or peripheral regional anesthesia techniques * Body mass index (BMI) greater than 35 kg/m² * Known allergy or hypersensitivity to local anesthetics or opioids * Presence of significant organ dysfunction (e.g., severe hepatic or renal disease)

Design outcomes

Primary

MeasureTime frameDescription
Requirement for Rescue Analgesia Within 24 HoursWithin the first 24 hours postoperativelyThe primary outcome is the number of participants who require rescue analgesia within the first 24 hours after cesarean delivery. Rescue analgesia is administered when the Numeric Rating Scale (NRS) pain score exceeds 4 and consists of intravenous tramadol given according to the institutional protocol.

Secondary

MeasureTime frameDescription
Postoperative Pain Intensity (NRS) at Rest0, 3, 6, 12, and 24 hours postoperativelyPain intensity at rest assessed using the Numeric Rating Scale (NRS, 0-10; higher scores indicate worse pain) at predefined postoperative time points.
Postoperative Pain Intensity (NRS) During Activity0, 3, 6, 12, and 24 hours postoperativelyPain intensity during activity assessed using the Numeric Rating Scale (NRS, 0-10; higher scores indicate worse pain) at predefined postoperative time points.
Postoperative Nausea and Vomiting (PONV) Severity Score0, 3, 6, 12, and 24 hours postoperativelySeverity of postoperative nausea and vomiting assessed using a 0-4 verbal rating scale at predefined postoperative time points.
Pruritus Severity Score0, 3, 6, 12, and 24 hours postoperativelySeverity of pruritus assessed using a 0-3 scale at predefined postoperative time points.
Obstetric Quality of Recovery (ObsQoR-11T) Total Score24 and 48 hours postoperativelyQuality of recovery assessed using the Obstetric Quality of Recovery-11T (ObsQoR-11T) questionnaire. Total score range is 0-110, with higher scores indicating better recovery.

Countries

Turkey (Türkiye)

Contacts

STUDY_DIRECTORİlke TAMDOGAN

Giresun University Faculty of Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026